Core Insights - The Cooper Companies (COO) is currently more attractive to value investors compared to Merit Medical (MMSI) based on various financial metrics and rankings [1][3][7] Valuation Metrics - COO has a forward P/E ratio of 18.10, while MMSI has a forward P/E of 24.27, indicating that COO is potentially undervalued [5] - The PEG ratio for COO is 1.79, compared to MMSI's PEG ratio of 2.39, suggesting that COO has a better balance between price and expected earnings growth [5] - COO's P/B ratio is 1.77, significantly lower than MMSI's P/B of 3.51, further supporting the argument that COO is more attractively valued [6] Rankings and Grades - COO holds a Zacks Rank of 2 (Buy), while MMSI has a Zacks Rank of 3 (Hold), indicating a stronger earnings outlook for COO [3] - The Value grade for COO is B, whereas MMSI has a Value grade of C, reflecting the superior valuation metrics of COO [6]

Group 1 - The Cooper Companies (COO) closed at $73.48, with a 0.8% gain over the past four weeks, and analysts set a mean price target of $92.93, indicating a 26.5% upside potential [1] - The mean estimate consists of 15 short-term price targets with a standard deviation of $7.52, where the lowest estimate is $76.00 (3.4% increase) and the highest is $105.00 (42.9% increase) [2] - Analysts show strong agreement on COO's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for COO has increased by 0.1% over the past month, with one estimate going higher and no negative revisions [12] - COO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - The Cooper Companies, Inc. is expected to report strong third-quarter fiscal 2025 results, with anticipated revenue growth of 5.4% year-over-year and earnings per share (EPS) growth of 8.2% [2][10]. Group 1: Financial Performance - The Zacks Consensus Estimate for revenues is $982 million, reflecting a 5.4% increase from the previous year [2]. - The consensus estimate for earnings is 92 cents per share, indicating an 8.2% improvement from the prior-year period [2]. - The company has consistently beaten earnings estimates, with an average surprise of 3.18% over the last four quarters [1]. Group 2: Segment Performance - Cooper Companies operates under two main segments: CooperVision (CVI) and CooperSurgical (CSI), both of which have shown strength recently [3]. - The CVI segment is expected to benefit from rising demand for contact lenses, with projected sales growth of 6-7% in fiscal 2025 [8]. - The CSI segment may face challenges due to weak fertility demand, but growth in minimally invasive surgical devices is expected to partially offset this weakness [11][12]. Group 3: Product Demand and Innovations - The CVI segment has seen solid growth across all geographies, particularly in The Americas, and is expected to continue this trend [5]. - Strong demand for premium brands like MyDay is anticipated to persist, supported by new market availability and expanded product offerings [6]. - The company is also launching new products, such as MyDay Energy in Canada and upgraded Clarity One Day Sphere in Japan, which are expected to contribute to revenue growth [4]. Group 4: Market Trends and Challenges - The overall market for contact lenses is projected to grow by 4-6% in 2025, benefiting Cooper Companies due to its leadership in several categories [5]. - The fertility segment is experiencing a decline, particularly in the Asia-Pacific region, which may impact overall sales [12]. - Despite challenges in the fertility market, the company anticipates continued interest in its PARAGARD product, although sales may decline in the upcoming quarter [13].

Core Insights - Analysts project The Cooper Companies (COO) will report quarterly earnings of $1.06 per share, a 10.4% increase year over year, with revenues expected to reach $1.07 billion, reflecting a 6.2% increase from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a collective reevaluation by analysts [1][2] Revenue Estimates - Revenue by Category - CVI is forecasted to reach $723.97 million, indicating a year-over-year change of +7.2% [4] - Revenue by Category - CSI is expected to be $343.37 million, suggesting a change of +4.9% year over year [4] - Revenue by Category - CSI - Office and surgical is projected at $209.17 million, reflecting a +5.7% change from the prior-year quarter [4] - Revenue by Category - CSI - Fertility is estimated at $134.62 million, indicating a +4.1% change from the year-ago quarter [5] - Revenue by Category - CVI - Sphere, other is predicted to be $371.00 million, showing a +6.2% change from the year-ago quarter [5] - Revenue by Category - CVI - Toric and multifocal is expected to reach $352.82 million, indicating an +8.1% change from the prior-year quarter [6] Geographic Revenue Estimates - Revenue by Geography - Americas is projected at $311.49 million, reflecting a +11.3% change from the year-ago quarter [6] - Revenue by Geography - Asia Pacific is expected to be $143.68 million, suggesting a +3.1% year-over-year change [6] - Revenue by Geography - EMEA is forecasted to reach $267.71 million, indicating a +4.4% year-over-year change [7] Stock Performance - Shares of The Cooper Companies have shown a return of -1% over the past month, compared to the Zacks S&P 500 composite's +1.1% change [7] - The company holds a Zacks Rank 3 (Hold), indicating expectations to mirror overall market performance in the near future [7]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for The Cooper Companies, driven by higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - The Cooper Companies is expected to report quarterly earnings of $1.06 per share, reflecting a +10.4% year-over-year change, with revenues projected at $1.07 billion, up 6.2% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a positive Earnings ESP of +0.58% for The Cooper Companies, suggesting a likelihood of beating the consensus EPS estimate [12]. Historical Performance - The Cooper Companies has beaten consensus EPS estimates in three out of the last four quarters, with a recent surprise of +3.23% [13][14]. Additional Considerations - While an earnings beat may influence stock movement, other factors can also play a significant role in stock performance post-earnings release [15][17].

Core Insights - The Cooper Companies, Inc. (COO) is focusing on strategic investments in innovation and has a diversified product base that supports long-term growth, although it faces near-term macro and inventory challenges, particularly in fertility and global consumer spending [1] Financial Performance - COO's shares have declined by 20% this year, contrasting with a 2.3% decline in the industry and a 9.6% increase in the S&P 500 Index [2] - The company has a market capitalization of $14.65 billion and is projected to see a 10.1% improvement in its bottom line over the next five years, with earnings beating estimates in three of the last four quarters [2][3] Operational Highlights - COO achieved solid organic top-line growth with adjusted earnings per share (EPS) increasing by 14% year over year to 96 cents, and operating margin expanded to 24.9% due to efficiency gains and disciplined cost management [4][8] - The MyDay daily silicone hydrogel lenses and MySight myopia management products have shown significant growth, with increases of 10% and 35% year over year, respectively [5][8] - The surgical portfolio, particularly CooperSurgical, reported an 8% revenue growth, with office-based surgical devices and PARAGARD IUDs growing by 13% and 18%, respectively [6][9] Challenges - Fertility revenue growth has slowed to 3%, attributed to declining cycles in Asia and deferred spending by clinics, leading management to revise growth expectations for the fertility segment to low-single-digit growth for fiscal 2025 [10] - The company is facing inventory and channel destocking pressures, which are impacting revenue visibility despite strong underlying demand [11] - COO anticipates a $4 million tariff impact on fiscal 2025 cost of goods sold (COGS) and a 3% EPS headwind in fiscal 2026 due to potential tariff and foreign exchange risks [12] Revenue Estimates - The Zacks Consensus Estimate for fiscal 2025 revenues is $4.12 billion, indicating a growth of 5.7% from the previous year, with adjusted EPS expected to improve by 10% to $4.06 [13]

Company Overview - CooperCompanies is a leading global medical device company with a focus on enhancing people's experiences through its two business units: CooperVision and CooperSurgical [2] - CooperVision is a prominent player in the contact lens industry, while CooperSurgical specializes in fertility and women's healthcare [2] - The company is headquartered in San Ramon, California, employs over 16,000 people, and sells products in more than 130 countries, positively impacting over 50 million lives annually [2] Upcoming Events - CooperCompanies will participate in the Wells Fargo Healthcare Conference on September 3, 2025, with President and CEO Al White representing the company [1] - The session is scheduled for 3:00 PM ET, and a webcast will be available for investors and interested parties [1]

Analyst's Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or a ...

Industry Overview - The Zacks Medical - Dental Supplies industry is experiencing weakness due to rising U.S. tariffs on trading partners, particularly China, which are expected to impact sales through 2025 [1] - Demand for elective procedures in the U.S. is declining, affecting sales across various product lines, including CAD/CAM and imaging products [2] - The global dental industry is projected to reach $610.4 billion with a CAGR of 4.5% from 2023 to 2032, indicating long-term growth potential despite current challenges [2] Major Trends - The aging population in the U.S. is a significant driver for the dental equipment market, with 55.8 million people aged 65 and above reported in 2020 [5] - Technological innovations such as CAD/CAM systems and AI diagnostics are enhancing treatment efficacy and expanding product use [6] - There is a growing emphasis on preventive care, leading to increased consumption of preventive dental products [6] - Trends towards minimally invasive and cosmetic dentistry are expanding market segments for specialized dental consumables [7] - Emerging markets, particularly in Asia-Pacific, are experiencing faster growth rates due to rising healthcare expenditure and improved access to care [8] Economic Impact - U.S. tariffs have significantly increased costs on essential imported dental items, with tariffs ranging from 10% to over 50%, leading to higher operational costs for manufacturers and distributors [10] - The industry is gradually shifting supply chains towards domestic production to mitigate tariff exposure, while dental associations are advocating for tariff exemptions [10] Industry Performance - The Zacks Medical Dental Supplies industry has underperformed compared to the broader sector and the S&P 500, with a collective decline of 0.4% over the past year [13] - The industry is currently trading at a forward P/E of 16.05X, lower than the S&P 500's 22.7X and the sector's 18.4X [16] Company Insights - West Pharmaceutical is expected to sustain growth momentum through 2025, with projected revenues between $3.04 billion and $3.06 billion, reflecting an organic growth of 3-3.75% [22] - McKesson is experiencing strong operational momentum, with a projected revenue gain of 13.3% for fiscal 2025 [31] - Cardinal Health anticipates adjusted EPS in the range of $8.05-$8.15 for fiscal 2025, despite facing pricing pressures and inflationary impacts [37] - Cooper Companies expects revenue growth of approximately 5.7% for 2025, supported by strong demand in both CooperVision and CooperSurgical segments [43]

Core Viewpoint - The Cooper Companies (COO) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - For the fiscal year ending October 2025, The Cooper Companies is expected to earn $4.06 per share, with a 1.9% increase in the Zacks Consensus Estimate over the past three months [8]. Investment Implications - The upgrade to Zacks Rank 2 suggests that The Cooper Companies is positioned in the top 20% of Zacks-covered stocks based on earnings estimate revisions, indicating potential for market-beating returns [10]. - Rising earnings estimates and the corresponding rating upgrade signal an improvement in the company's underlying business, likely leading to increased stock prices [5][10].